Skip to main content
Premium Trial:

Request an Annual Quote

VistaGen, Capsant To Co-market Stem Cell-based Drug Screening Platforms

NEW YORK (GenomeWeb News) — VistaGen will offer its stem cell-based screening platform with Capsant's cell culture system under a commercialization agreement focused on technologies for new programs that would use stem cell technologies to change the clinical trial process, VistaGen said today.

Vistagen's "Clinical Trials in a Test Tube" platform is aimed at generating predictive information about drug trial failures, particularly those involving liver and heart toxicity. Capsant's OrganDot 3D technology is a high-throughput, in vitro drug testing system using stem cell-based 3D tissue cultures.

VistaGen CEO Ralph Snodgrass said the agreement enables the two companies to offer "reproducible, mature, and functional human cells that grow as 3D 'micro-organs' in a commercially scalable platform with integrated analytical capabilities."

"This new agreement advances our common goal of providing new-generation drug development tools that are a vital necessity to improve drug R&D productivity in the pharmaceutical industry," he continued.

Capsant is headquartered in Southampton, UK, and VistaGen is based in South San Francisco.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.